Faculty Publications

Clinically important difference in quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-A (IFN)

Mallick R, Hudes G, Levy DE

Clinically important difference in quality-adjusted survival in patients with advanced renal cell carcinoma receiving first-line treatment with temsirolimus (TEMSR) or interferon-A (IFN)

Value in Health. 2007 Nov-Dec;10(6):A342-A342.

Abstract

Last updated on Saturday, November 21, 2009